3 Year Absolute Returns
60.65% ↑
NAV (₹) on 16 Nov 2026
585.10
1 Day NAV Change
-0.02%
Risk Level
Very High Risk
Rating
-
Nippon India Pharma Fund is a Equity mutual fund categorized under Sector, offered by Nippon Life India Asset Management Ltd.. Launched on 05 Jun 2004, investors can start with a minimum SIP of ₹100 ... Read more
AUM
₹ 9,087.25 Cr
| Sectors | Weightage |
|---|---|
| Pharmaceuticals | 78.01% |
| Hospitals & Medical Services | 20.80% |
| Chemicals - Speciality | 0.81% |
| Treps/Reverse Repo | 0.52% |
| Name | Weightage | Value (in Cr.) | Sector |
|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 11.55% | ₹ 1,049.97 | Pharmaceuticals |
| Divi's Laboratories Limited | 6.73% | ₹ 611.99 | Pharmaceuticals |
| Cipla Limited | 6.21% | ₹ 564.67 | Pharmaceuticals |
| Lupin Limited | 6.16% | ₹ 559.86 | Pharmaceuticals |
| Dr. Reddy's Laboratories Limited | 6.13% | ₹ 556.82 | Pharmaceuticals |
| Apollo Hospitals Enterprise Limited | 5.10% | ₹ 463.62 | Hospitals & Medical Services |
| Mankind Pharma Limited | 4.40% | ₹ 399.74 | Pharmaceuticals |
| Sai Life Sciences Limited | 4.04% | ₹ 366.91 | Pharmaceuticals |
| Ajanta Pharma Limited | 3.53% | ₹ 320.68 | Pharmaceuticals |
| Max Healthcare Institute Limited | 3.31% | ₹ 300.84 | Hospitals & Medical Services |
| IPCA Laboratories Limited | 2.90% | ₹ 263.10 | Pharmaceuticals |
| GlaxoSmithKline Pharmaceuticals Limited | 2.83% | ₹ 256.78 | Pharmaceuticals |
| Gland Pharma Limited | 2.73% | ₹ 247.84 | Pharmaceuticals |
| Vijaya Diagnostic Centre Limited | 2.66% | ₹ 241.67 | Hospitals & Medical Services |
| Piramal Pharma Limited | 2.61% | ₹ 237.41 | Pharmaceuticals |
| MedPlus Health Services Limited | 2.26% | ₹ 205.59 | Pharmaceuticals |
| Fortis Healthcare Limited | 2.25% | ₹ 204.04 | Hospitals & Medical Services |
| Abbott India Limited | 2.22% | ₹ 201.35 | Pharmaceuticals |
| Dr. Lal Path Labs Limited | 2.10% | ₹ 190.75 | Hospitals & Medical Services |
| Thyrocare Technologies Limited | 1.93% | ₹ 175.13 | Hospitals & Medical Services |
| Alkem Laboratories Limited | 1.82% | ₹ 165.51 | Pharmaceuticals |
| Narayana Hrudayalaya Limited | 1.56% | ₹ 141.73 | Hospitals & Medical Services |
| Syngene International Limited | 1.55% | ₹ 141.01 | Pharmaceuticals |
| Aurobindo Pharma Limited | 1.42% | ₹ 128.93 | Pharmaceuticals |
| Suraksha Diagnostic Limited | 1.36% | ₹ 123.26 | Hospitals & Medical Services |
| Emcure Pharmaceuticals Limited | 1.32% | ₹ 119.97 | Pharmaceuticals |
| Anthem Biosciences Limited | 1.30% | ₹ 117.69 | Pharmaceuticals |
| Pfizer Limited | 1.29% | ₹ 117.36 | Pharmaceuticals |
| Akums Drugs and Pharmaceuticals Limited | 1.09% | ₹ 98.90 | Pharmaceuticals |
| Sanofi India Limited | 1.06% | ₹ 96.21 | Pharmaceuticals |
| Biocon Limited | 0.97% | ₹ 88.09 | Pharmaceuticals |
| Natco Pharma Limited | 0.90% | ₹ 81.37 | Pharmaceuticals |
| Sanofi Consumer Healthcare India Limited | 0.81% | ₹ 73.55 | Chemicals - Speciality |
| Molbio Diagnostics Limited | 0.53% | ₹ 48.45 | Hospitals & Medical Services |
| Triparty Repo | 0.52% | ₹ 47.35 | Others |
| AstraZeneca Pharma India Limited | 0.46% | ₹ 42.15 | Pharmaceuticals |
| Indoco Remedies Limited | 0.38% | ₹ 34.40 | Pharmaceuticals |
| Concord Biotech Limited | 0.15% | ₹ 13.92 | Pharmaceuticals |
| Annualised returns | ||||
|---|---|---|---|---|
| 9M | 1Y | 2Y | 3Y | |
| Fund returns | 15.59% | 12.70% | 8.41% | 17.12% |
| Category returns | 7.34% | 5.08% | 9.77% | 22.47% |
The primary investment objective of the scheme is to seek to generate continuous returns by investing in equity and equity related or fixed-income securities of Pharma and other associated companies.
|
Scheme Name
|
NAV
|
Returns
1Y
3Y
5Y
|
AUM (Cr)
|
Expense Ratio
|
Risk Meter
|
||
|---|---|---|---|---|---|---|---|
|
Nippon India Taiwan Equity fund - Direct Plan
Sector
Direct
|
₹26.37 | 50.25% | 184.01% | 0.00% | ₹963 | 1.06% |
Very High
|
|
Nippon India Taiwan Equity fund - Direct Plan
Sector
Direct
|
₹26.37 | 50.25% | 184.01% | 0.00% | ₹963 | 1.06% |
Very High
|
|
Nippon India Taiwan Equity fund - Direct Plan
Sector
Direct
|
₹26.37 | 50.25% | 184.01% | 0.00% | ₹963 | 1.06% |
Very High
|
|
Nippon India Taiwan Equity Fund
Sector
Regular
|
₹24.56 | 48.26% | 172.60% | 0.00% | ₹963 | 2.34% |
Very High
|
|
Nippon India Taiwan Equity Fund
Sector
Regular
|
₹24.56 | 48.26% | 172.60% | 0.00% | ₹963 | 2.34% |
Very High
|
|
Nippon India Taiwan Equity Fund
Sector
Regular
|
₹24.56 | 48.26% | 172.60% | 0.00% | ₹963 | 2.34% |
Very High
|
|
HDFC Defence Fund - Direct Plan
Sector
Direct
|
₹30.12 | 18.09% | 129.70% | 0.00% | ₹11,131 | 0.89% |
Very High
|
|
HDFC Defence Fund - Direct Plan
Sector
Direct
|
₹30.12 | 18.09% | 129.70% | 0.00% | ₹11,131 | 0.89% |
Very High
|
|
HDFC Defence Fund - Direct Plan
Sector
Direct
|
₹30.12 | 18.09% | 129.70% | 0.00% | ₹11,131 | 0.89% |
Very High
|
|
HDFC Pharma and Healthcare Fund - Direct Plan
Sector
Direct
|
₹23.46 | 30.32% | 124.36% | 0.00% | ₹3,666 | 1.03% |
Very High
|
What is the current NAV of Nippon India Pharma Fund Regular Growth?
What is the fund size (AUM) of Nippon India Pharma Fund Regular Growth?
What are the historical returns of Nippon India Pharma Fund Regular Growth?
What is the risk level of Nippon India Pharma Fund Regular Growth?
What is the minimum investment amount for Nippon India Pharma Fund Regular Growth?
Disclaimer: This is 3rd Party content/feed, viewers are requested to use their discretion and conduct proper diligence before investing, GoodReturns does not take any liability on the genuineness and correctness of the information in this article